Skip to content

rTMS for the Treatment of Primary Progressive Aphasia: A Randomized Controlled Trial

Repetitive Transcranial Magnetic Stimulation for the Treatment of Primary Progressive Aphasia: A Randomized Controlled Tria

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03448133
Enrollment
0
Registered
2018-02-27
Start date
2018-03-01
Completion date
2021-12-31
Last updated
2020-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aphasia, Primary Progressive, Repetitive Transcranical Magnetic Stimulation

Brief summary

The primary progressive aphasia (PPA) is a neurodegenerative condition characterized by a gradual, irreversible decline of language function (Mesulam, 2001). There are no known treatments for PPA so far. The relentless progression of PPA symptoms eventually leads to a profound impairment in communication ability and, ultimately, to more generalized deficits of cognition. Some cases and small studies reported that Transcranial Magnetic Stimulation (TMS), one of the non-invasive neuromodulation tech, can be employed to facilitate language production and improve the language ability in patients with PPA. Herein we will explore the tolerance and efficacy of TMS for the treatment of PPA by the randomized controlled trial .Meanwhile the functional MRI tech will be used to investigate the neural network changing in the procedure

Interventions

The device is made in London,UK

Sponsors

Peking Union Medical College Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
35 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

All participants had also been evaluated previously by a behavioral neurologist at the Peking Union Medical College Hospital and had been clinically diagnosed with a variant of PPA.

Exclusion criteria

1. Scored below 15 on the mini-mental state exam (MMSE) due to concerns that global cognitive impairment might preclude their ability to follow the directions and interfere with task performance. 2. Had a history of seizures or unexplained loss of consciousness, pregnancy, surgical breach of the skull, or any other medical or surgical contraindication to receiving noninvasive brain stimulation. 3. Is unable to complete the treatment and evaluations

Design outcomes

Primary

MeasureTime frameDescription
Boston naming test evaluationBaselineAssessment of the language production
Western Aphasia Battery(WAB) Speech fluencyBaselineAssessment of the language production
Repetition Part of WABBaselineAssessment of the repetition ability
Word recognition Part of WABBaselineAssessment of the reading
Syntax comprehension Part of Bilingual Aphasia Battery( Standard modern Chinese version)BaselineAssessment of the grammar ability

Secondary

MeasureTime frameDescription
fMRI parameters(strength, efficiency, clustering coefficient, and characteristic path length)BaselineGraph theoretical analysis of the speech/language network

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026